Trial Profile
A Post-approval Study of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia
- Focus Therapeutic Use
- Acronyms ONYX PAS
- Sponsors Medtronic
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Oct 2021 Planned End Date changed from 1 Aug 2023 to 1 Sep 2022.
- 05 Apr 2021 Planned End Date changed from 1 Feb 2021 to 1 Aug 2023.